BASILEA N/ CH0011432447 /
| 12/10/2024 5:30:59 PM | Chg. +0.650 | Volume | Bid5:40:00 PM | Ask5:40:00 PM | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 41.200CHF | +1.60% | 21,533 Turnover: 883,649.100 |
41.000Bid Size: 200 | 41.400Ask Size: 200 | 539.71 mill.CHF | - | 47.36 |
GlobeNewswire
8/27
European Commission Decision to approve the pediatric use of antifungal Cresemba® (isavuconazole) an...
GlobeNewswire
8/21
Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone paym...
GlobeNewswire
8/13
Basilea reports strong 2024 half-year results and significantly increases full-year revenue and prof...
GlobeNewswire
6/20
Basilea partners oncology drug candidate lisavanbulin with Glioblastoma Foundation
GlobeNewswire
5/16
Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone paym...
GlobeNewswire
5/3
Basilea reports presentation of new data for ceftobiprole (Zevtera®) at ESCMID Global 2024
GlobeNewswire
4/24
Basilea shareholders approve all proposals of the board of directors at the annual general meeting
GlobeNewswire
4/9
Basilea awarded CARB-X grant to develop recently acquired novel class of antibiotics
GlobeNewswire
4/4
Basilea announces US FDA approval of antibiotic ZEVTERA® (ceftobiprole medocaril) for three indicati...
GlobeNewswire
3/11
Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers mile...
GlobeNewswire
2/13
Basilea reports strong 2023 full-year results with profitability significantly above guidance, whils...
GlobeNewswire
1/19
Cresemba® sales in Latin America trigger first sales milestone payment to Basilea
GlobeNewswire
12/11/2023
Basilea announces that FDA approves expanded use of antifungal Cresemba® (isavuconazole) in the Unit...
GlobeNewswire
11/20/2023
Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers thir...
GlobeNewswire
11/13/2023
Basilea announces acquisition of fosmanogepix, a phase-3-ready broad-spectrum antifungal
GlobeNewswire
10/31/2023
Basilea announces exclusive license and option agreement for potential first-in-class clinical-stage...
GlobeNewswire
10/19/2023
Basilea announces acquisition of novel clinical-stage antifungal for treatment of Aspergillus mold i...
GlobeNewswire
10/17/2023
Basilea reports new data for ceftobiprole (Zevtera®) presented at US IDWeek Congress 2023
GlobeNewswire
10/2/2023
Basilea announces FDA acceptance of New Drug Application for antibiotic ceftobiprole
